Regeneron Pharmaceuticals has received approval from the European Commission for Eylea in the treatment of visual impairment from diabetic macular edema, the company announced.Bayer Healthcare plans to launch Eylea (aflibercept) for DME in the European…
Minimal further treatment for DME needed at year 5 in Protocol I study
SAN DIEGO — Visual acuity gains achieved during the first year of treatment with ranibizumab and prompt or deferred laser in patients with diabetic macular edema are maintained through 5 years, with minimal further treatment needed after 3 years, according to a speaker here.John A. Wells III, MD, described the 5-year extended follow-up of the Diabetic Retinopathy Clinical Research Network (DRCR) Protocol I for treatment of DME at the American Society of Retina Specialists annual meeting.
Speaker discusses lesion characteristics from HOME study
At the American Society of Retina Specialists meeting in San Diego, Judy Kim, MD, discusses findings on lesion characteristics from the Foresee HOME study as part of the AREDS 2 study.
Optometrists notice increase in young people suffering from potentially serious eye conditions
The number of young people who are being diagnosed with serious eye conditions is thought to be growing, according to a survey of Optometrists released today.
European Commission grants EYLEA licence for the treatment of visual impairment due to diabetic macular oedema
Bayer HealthCare today announces that EYLEA® (aflibercept solution for injection) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular…
Surprising research results could lead to new ways to help the visually impaired better navigate everyday life
Visual impairment comes in many forms, and it’s on the rise in America.The Enactive Torch uses infra-red sensors to “see” objects in front of it.